Trial Profile
A Phase Ib/II , Open-label , Investigator-initiated Trail of An Anti-PD-1 Inhibitor SHR-1210 in Combination With A CDK4/6 Inhibitor SHR6390 in Patients With Advanced Colorectal Cancer, Non-small Cell Lung Cancer and Hepatocellular Carcinoma
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Dalpiciclib (Primary)
- Indications Colorectal cancer; Liver cancer; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2018 New trial record